Citigroup’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-14,600
| Closed | -$2.57M | – | 5958 |
|
|
2025
Q4 | $2.57M | Hold |
14,600
| – | – | ﹤0.01% | 2492 |
|
|
2025
Q3 | $2.05M | Hold |
14,600
| – | – | ﹤0.01% | 2661 |
|
|
2025
Q2 | $1.83M | Sell |
14,600
-14,900
| -51% | -$1.86M | ﹤0.01% | 2721 |
|
|
2025
Q1 | $4.04M | Buy |
29,500
+2,700
| +10% | +$386K | ﹤0.01% | 2101 |
|
|
2024
Q4 | $4.1M | Buy |
26,800
+22,000
| +458% | +$3.71M | ﹤0.01% | 2166 |
|
|
2024
Q3 | $930K | Sell |
4,800
-15,000
| -76% | -$3.14M | ﹤0.01% | 3316 |
|
|
2024
Q2 | $4.59M | Buy |
19,800
+15,000
| +313% | +$3.26M | ﹤0.01% | 1696 |
|
|
2024
Q1 | $1.04M | Sell |
4,800
-36,900
| -88% | -$8.64M | ﹤0.01% | 2997 |
|
|
2023
Q4 | $10.8M | Sell |
41,700
-25,100
| -38% | -$6.16M | 0.01% | 1177 |
|
|
2023
Q3 | $17.2M | Buy |
66,800
+12,000
| +22% | +$3.21M | 0.01% | 849 |
|
|
2023
Q2 | $15.6M | Buy |
54,800
+21,800
| +66% | +$6.49M | 0.01% | 936 |
|
|
2023
Q1 | $9.17M | Buy |
33,000
+10,500
| +47% | +$2.91M | 0.01% | 1204 |
|
|
2022
Q4 | $6.23M | Sell |
22,500
-35,000
| -61% | -$9.89M | 0.01% | 1362 |
|
|
2022
Q3 | $15.4M | Buy |
+57,500
| New | +$12.2M | 0.01% | 922 |
|
|
2021
Q1 | – | Sell |
-177,800
| Closed | -$43.5M | – | 6297 |
|
|
2020
Q4 | $43.5M | Buy |
177,800
+6,000
| +3% | +$1.55M | 0.03% | 605 |
|
|
2020
Q3 | $48.7M | Sell |
171,800
-13,500
| -7% | -$3.77M | 0.03% | 461 |
|
|
2020
Q2 | $49.6M | Sell |
185,300
-73,600
| -28% | -$22.1M | 0.04% | 395 |
|
|
2020
Q1 | $81.9M | Sell |
258,900
-9,400
| -4% | -$2.85M | 0.07% | 226 |
|
|
2019
Q4 | $79.6M | Sell |
268,300
-17,600
| -6% | -$4.88M | 0.06% | 314 |
|
|
2019
Q3 | $66.6M | Buy |
285,900
+31,500
| +12% | +$7.33M | 0.05% | 351 |
|
|
2019
Q2 | $59.5M | Buy |
254,400
+78,200
| +44% | +$18.1M | 0.05% | 372 |
|
|
2019
Q1 | $41.6M | Sell |
176,200
-131,700
| -43% | -$41.5M | 0.04% | 466 |
|
|
2018
Q4 | $92.7M | Buy |
307,900
+3,700
| +1% | +$1.18M | 0.09% | 203 |
|
|
2018
Q3 | $107M | Buy |
304,200
+15,400
| +5% | +$5.3M | 0.1% | 181 |
|
|
2018
Q2 | $83.8M | Buy |
288,800
+31,900
| +12% | +$8.97M | 0.08% | 211 |
|
|
2018
Q1 | $70.3M | Buy |
256,900
+33,500
| +15% | +$10.4M | 0.06% | 294 |
|
|
2017
Q4 | $71.2M | Buy |
223,400
+22,800
| +11% | +$7.31M | 0.06% | 317 |
|
|
2017
Q3 | $62.8M | Buy |
200,600
+58,600
| +41% | +$17.4M | 0.05% | 324 |
|
|
2017
Q2 | $38.5M | Sell |
142,000
-51,800
| -27% | -$13.7M | 0.03% | 452 |
|
|
2017
Q1 | $53M | Sell |
193,800
-131,700
| -40% | -$37.2M | 0.05% | 341 |
|
|
2016
Q4 | $92.3M | Buy |
325,500
+137,300
| +73% | +$40.7M | 0.08% | 221 |
|
|
2016
Q3 | $58.9M | Buy |
188,200
+20,000
| +12% | +$5.92M | 0.06% | 298 |
|
|
2016
Q2 | $40.7M | Buy |
168,200
+38,100
| +29% | +$10M | 0.04% | 377 |
|
|
2016
Q1 | $33.9M | Sell |
130,100
-80,200
| -38% | -$21.2M | 0.04% | 416 |
|
|
2015
Q4 | $64.4M | Buy |
210,300
+60,400
| +40% | +$17.4M | 0.06% | 282 |
|
|
2015
Q3 | $43.7M | Sell |
149,900
-6,100
| -4% | -$2.01M | 0.04% | 381 |
|
|
2015
Q2 | $63M | Buy |
156,000
+20,100
| +15% | +$8.07M | 0.06% | 320 |
|
|
2015
Q1 | $57.4M | Sell |
135,900
-65,600
| -33% | -$25.9M | 0.06% | 319 |
|
|
2014
Q4 | $68.4M | Sell |
201,500
-45,000
| -18% | -$14.6M | 0.06% | 321 |
|
|
2014
Q3 | $81.5M | Buy |
246,500
+8,900
| +4% | +$2.93M | 0.07% | 244 |
|
|
2014
Q2 | $74.9M | Buy |
237,600
+5,800
| +3% | +$1.75M | 0.07% | 256 |
|
|
2014
Q1 | $70.9M | Sell |
231,800
-16,000
| -6% | -$5.08M | 0.07% | 230 |
|
|
2013
Q4 | $69.3M | Sell |
247,800
-47,600
| -16% | -$12.3M | 0.06% | 280 |
|
|
2013
Q3 | $71.1M | Buy |
295,400
+33,200
| +13% | +$7.43M | 0.07% | 259 |
|
|
2013
Q2 | $56.4M | Buy |
+262,200
| New | +$56M | 0.06% | 280 |
|
Other funds holding BIIB
VCM
VPM
Citigroup's BIIB Position: Q1 2026 in Review
Citigroup reduced its Biogen (BIIB) stake by 13% in Q1 2026, selling an estimated $13.5M and leaving 500,507 shares worth $91.8M. The position accounts for 0.04% of the portfolio, ranked #433.
Citigroup first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $101M in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Citigroup held 500,507 shares of Biogen worth $91.8M as of Q1 2026.
- Citigroup sold 73,337 Biogen shares in Q1 2026, an estimated $13.5M.
- Biogen made up 0.04% of Citigroup's portfolio in Q1 2026, its #433 holding.
- Citigroup first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Biogen position peaked at $101M in Q4 2025.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.